, Article L5122-6 of the French Public Health Code

, Regulation (EC) 1394/2007 on advanced therapy medicinal products, OJ, vol.324, pp.121-137

, /23/EC on tissues and cells (OJ L102/48-58), or the Directive 2002/98/EC on human blood and blood components, vol.33, pp.30-40, 2004.

, The Regulation also allows SMEs a 90% reduction in the fees (and other applicants a 65% reduction in the fee) that would otherwise be payable to the EMA for scientific advice

G. Chondrocelect, . Maci, . Provenge, . Holoclar, . Imlygic et al.,

, Marketing authorizations for Provenge, Chondrocelect, MACI and Glybera were withdrawn at the request of the marketing authorization holders

E. Brosset and A. Mahalatchimy, , p.197, 2017.

C. Chabannon, Les unités de thérapie cellulaire à l'épreuve de la règlementation sur les médicaments de thérapie innovante, p.576, 2014.

D. Courtney, Adaptive pathways" to drug authorisation: adapting to industry?, pp.354-4437, 2016.

D. Grove-valdeyron and N. , , 2014.

D. Grove-valdeyron and N. , Les nouveaux enjeux de la politique pharmaceutique européenne: pour des produits de santé sûrs, 2019.

D. Grove-valdeyron, N. , and M. , , 2011.

M. Ermisch, Payers' views of the changes arising through the possible adoption of Adaptive Pathways, Front. Pharmacol, p.7, 2016.

R. Eurordis and . Diseases-europe, The voice of rare disease patients in Europe, Early access to medicines in Europe: Compassionate use to become a reality, p.2017

A. Faulkner and A. Mahalatchimy, The institutional and methodological politics of valuation and payment for regenerative medicine products in the UK, New Genetics and Society, 2018.

P. Feldschreiber, The Law and Regulation of Medicines, 2008.

A. Ferrario and P. Kanavos, Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in, Soc. Sci. Med, p.124, 2015.

A. Ferrario and P. Kanavos, Managed entry agreements for pharmaceuticals: the European experience, EMiNet, 2013.

J. Gardner, Are there specific translational challenges in regenerative medicine? Lessons from other fields, Regenerative Medicine, issue.7, p.885, 2015.

R. S. Goldberg, Medicinal Product Liability and Regulation, 2013.

R. Goldberg and J. Lonbay, Pharmaceutical Medicine, Biotechnology and European Law, 2001.

L. Hancher, The EU pharmaceutical markets: parameters and pathways, Health Systems Governance in Europe: the role of EU Law and Policy, p.635, 2010.

T. K. Hervey and J. V. Mchale, European Union Health Law, 2015.

T. K. Hervey, C. A. Young, and L. E. Bishop, Research Handbook in EU Health Law and Policy, 2017.

E. Jackson, R. Law, and . Of-medicines, , 2012.

A. Leca, C. Maurain, I. Moine-dupuis, and G. Rousset, Le monopole pharmaceutique et son avenir, (Cahier de Droit de la Santé juridiques, 2017.

F. Liberatore, UK calls for ban of parallel trade of prescription medicines -what are the EU competition law implications?, European Competition Law Review, vol.34, issue.4, 2013.

A. Mahalatchimy, La promotion de l'innovation en matière de santé: quelles logiques à l'oeuvre dans l'Union européenne?, vol.627

A. Mahalatchimy, Reimbursement of cell-based regenerative therapy in the UK and France, Medical Law Review, vol.24, issue.2, p.234, 2016.

A. Mahalatchimy, The legal landscape for Advanced Therapy Medicinal Products: material and institutional implementation of European Union rules, Journal of Law and Society, vol.39, issue.1, 2012.

A. Mahalatchimy, E. Rial-sebbag, D. Grove-valdeyron, N. Tournay, V. Cambon-thomsen et al., The European Medicines Agency: a public health European agency?, Medicine and Law Journal, vol.25, issue.1, p.31, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01560579

A. Mendoza-caminade, . Médicament, and . Droit, Droit français et européen, 2018.

N. Mihokovic, E. Experience, and . Perspective, Regulatory challenges in the drug-food continuum, IMI Stakeholder Forum, 2017.

T. J. Moore and C. D. Furberg, Electronic health data for postmarket surveillance: a vision not realized'(2015) 38 Drug Saf, p.26025018

G. Permanand and E. Mossialos, Constitutional Asymmetry and Pharmaceutical Policy-Making in the European Union, Journal of European Public Policy, vol.12, issue.4, 2005.

G. Permanand, M. E. Mckee, and M. , Regulating Medicines in Europe: the European Medicines Agency, Marketing Authorisation, Transparency and Pharmacovigilance, p.6, 2006.

, Clinical Medicine, vol.87

M. Pilgerstorfer, T. K. Hervey, Y. Ca, and L. E. Bishop, EU law and policy on pharmaceuticals marketing and post-market control including product liability, p.156, 2017.

T. Georgios, Limiting pharmaceutical parallel trade in the European Union: regulatory and economic justifications, European Law Review, vol.36, issue.3, p.385, 2011.